Registry Study on Biological Disease Profile and Clinical Outcome in Acute Myeloid Leukemia and Related Neoplasms, and Acute Leukemias of Ambiguous Lineage - The AMLSG Biology and Outcome (BiO)-Project (AMLSG BiO)

This study is currently recruiting participants. (see Contacts and Locations)
Verified July 2014 by University of Ulm
Sponsor:
Information provided by (Responsible Party):
Dr. Richard Schlenk, University of Ulm
ClinicalTrials.gov Identifier:
NCT01252485
First received: December 2, 2010
Last updated: July 22, 2014
Last verified: July 2014

December 2, 2010
July 22, 2014
July 2010
Not Provided
  • Completeness [ Designated as safety issue: No ]
    To register all patients with newly diagnosed AML in all AMLSG participating centers (completeness)
  • incidence of relevant genetic markers [ Designated as safety issue: No ]
    To perform timely analyses of relevant genetic markers (according to WHO 2008 classification) (incidences, treatment decision)
  • Event-free survival [ Time Frame: 10 years ] [ Designated as safety issue: No ]
    To assess clinical characteristics and outcome data (event-free survival [EFS], cumulative incidence of relapse [CIR], cumulative incidence of death [CID], overall survival [OS])
  • Cumulative incidence of relapse [ Time Frame: 10 years ] [ Designated as safety issue: No ]
    To assess clinical characteristics and outcome data (event-free survival [EFS], cumulative incidence of relapse [CIR], cumulative incidence of death [CID], overall survival [OS])
  • Cumulative incidence of death [ Time Frame: 10 years ] [ Designated as safety issue: No ]
    To assess clinical characteristics and outcome data (event-free survival [EFS], cumulative incidence of relapse [CIR], cumulative incidence of death [CID], overall survival [OS])
  • Overall survival [ Time Frame: 10 years ] [ Designated as safety issue: No ]
    To assess clinical characteristics and outcome data (event-free survival [EFS], cumulative incidence of relapse [CIR], cumulative incidence of death [CID], overall survival [OS])
  • Treatment decision (intensive, non-intensive, investigational) [ Designated as safety issue: No ]
    To perform timely analyses of relevant genetic markers (according to WHO 2008 classification) (incidences, treatment decision)
  • quality of life [ Time Frame: 5 years ] [ Designated as safety issue: No ]
    Quality of life assessed by the EORTC Quality of Life Core Questionnaire (QLQ-C30), supplemented by information on self-assessed concomitant diseases, late treatment effects, and demographics according to Messerer et al [40] initially, in first CR, one year, 3 and 5 years after initial diagnosis.
Same as current
Complete list of historical versions of study NCT01252485 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Registry Study on Biological Disease Profile and Clinical Outcome in Acute Myeloid Leukemia and Related Neoplasms, and Acute Leukemias of Ambiguous Lineage - The AMLSG Biology and Outcome (BiO)-Project
Registry Study on Biological Disease Profile and Clinical Outcome in Acute Myeloid Leukemia and Related Neoplasms, and Acute Leukemias of Ambiguous Lineage - The AMLSG Biology and Outcome (BiO)-Project

This is a registry study in adult patients with newly diagnosed AML

Investigator's sites: 50-60 sites in Germany and Austria

Estimated duration of observation of an individual patient:

10 years maximum

Objectives

  • To register all patients with newly diagnosed AML in all AMLSG participating centers (completeness)
  • To perform timely analyses of relevant genetic markers (according to WHO 2008 classification) (incidences, treatment decision)
  • To assess clinical characteristics and outcome data (event-free survival [EFS], cumulative incidence of relapse [CIR], cumulative incidence of death [CID], overall survival [OS])
  • To assess biological disease features and correlate with clinical outcome data (prognostic and predictive markers)
  • To store biosamples from all patients (eg, bone marrow, blood, plasma, buccal swap, sputum, skin biopsy samples)
  • To assess quality of life
Not Provided
Observational
Observational Model: Case-Only
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

patients with newly diagnosed AML in all AMLSG participating centers (50-60 centers in Germany and Austria)

Acute Myeloid Leukemia (AML)
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
Not Provided
Not Provided
Not Provided

Inclusion Criteria:

  • Patients with suspected diagnosis of acute myeloid leukemia or related precursor neoplasm, or acute leukemia of ambiguous lineage (classified according to the World Health Organization (WHO) classification)
  • Age ≥ 18 years. There is no upper age limit.
  • No prior chemotherapy* for leukemia except hydroxyurea to control hyperleukocytosis
  • Signed written informed consent *prior therapy of a preceding myelodysplastic syndrome or myeloproliferative neoplasm is allowed

Exclusion Criteria:

  • Severe neurological or psychiatric disorder interfering with ability to give an informed consent
  • No consent for registration, storage and processing of the individual disease characteristics and course as well as information of the family physician about study participation.
  • No consent for biobanking of patient's biological specimens and performance of analyses on stored material.
Both
18 Years and older
No
Contact: Richard F Schlenk, MD 49-731-500-45900 richard.schlenk@uniklinik-ulm.de
Germany
 
NCT01252485
AMLSG BiO
No
Dr. Richard Schlenk, University of Ulm
University of Ulm
Not Provided
Study Chair: Richard F Schlenk, MD University Hospital of Ulm
University of Ulm
July 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP